Dermata Therapeutics, Inc. (DRMA): Nasdaq/NYSE listing notice — Nasdaq Panel grants Dermata Therapeutics exception until Aug 14, 2025 to meet minimum bid price rule

Dermata Therapeutics, Inc.

Company received Nasdaq delisting notice on May 14, 2025 for failing minimum $1.00 bid price over 30 consecutive days.
Hearings Panel granted exception through August 14, 2025 to demonstrate compliance; suspension stayed during hearing process.
Dermata will seek shareholder approval for reverse stock split at July 15, 2025 annual meeting to regain compliance.
If compliance not achieved or other listing requirements unmet, common stock (DRMA) and warrants (DRMAW) may be delisted.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Dermata Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

July 2, 2025, the Panel notified the Company that it has granted Company’s request for an exception until August 14, 2025, to demonstrate compliance with the Minimum Bid Price Requirement (the “Exception”). Pursuant to the Exception, the Company is required to provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company’s ability to satisfy the terms of the Exception. The Company is actively pursuing measures to regain compliance with the Minimum Bid Price Requirement, including seeking shareholder approval for a r

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-018042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.